We are live on
!
Find out more
BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$1.11B
1-Year Est. Return
171.34%
This Fund
S&P 500
This Quarter
Est. Return
+9.82%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$838M
AUM Growth
-$14.9M
(-1.8%)
Cap. Flow
-$32.9M
Cap. Flow
% of AUM
-3.93%
Top 10 Holdings %
Top 10 Hldgs %
68.16%
Holding
36
New
1
Increased
4
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THRD
Third Harmonic Bio
THRD
|
+$41.1M |
| 2 |
X4 Pharmaceuticals
XFOR
|
+$3.88M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$3.7M |
| 4 |
Annexon
ANNX
|
+$1.95M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$162K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DVAX
Dynavax Technologies
DVAX
|
+$39.1M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$23.1M |
| 3 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$9.8M |
| 4 |
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
|
+$6.87M |
| 5 |
PANA
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
|
+$4.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.33% |
| 2 | Financials | 1.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Invivyd
IVVD
$216M
| $6.06M | 0.72% |
1,937,207
| – | – |
|
|
ARYE
27
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $4.91M | 0.59% |
500,000
| – | – |
|
|
BLSA
28
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $4.88M | 0.58% |
487,500
| – | – |
|
29
Nautilus Biotechnolgy
NAUT
$114M
| $4.24M | 0.51% |
2,000,000
| – | – |
|
30
Solid Biosciences
SLDB
$971M
| $3.7M | 0.44% |
528,661
| – | – |
|
|
APTX
31
DELISTED
Aptinyx Inc. Common Stock
APTX
| $3.27M | 0.39% |
8,891,758
| – | – |
|
|
FLACU
32
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
| $3.04M | 0.36% |
300,000
| – | – |
|
33
Spyre Therapeutics
SYRE
$9.18B
| $2.81M | 0.34% |
213,908
| – | – |
|
|
ARYD
34
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| – | – |
-700,000
| Closed | -$6.87M |
|
|
PANA
35
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| – | – |
-500,000
| Closed | -$4.88M |
|
|
RACB
36
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| – | – |
-1,000,000
| Closed | -$9.8M |
|
Similar funds
JTWM
HH
RIM
YL
FLAM
AIM
MTCM
CNC
Bain Capital Life Sciences Investors's Q3 2022 Portfolio in Review
As of Q3 2022, Bain Capital Life Sciences Investors held 36 positions worth $838M, down 1.8% from $853M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Bain Capital Life Sciences Investors withdrew a net $32.9M in Q3 2022, closing 3 positions and reducing 2 holdings. Its most notable exit was Research Alliance Corp. II Class A Common Stock, an estimated $9.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Financials.
Against the trend, Bain Capital Life Sciences Investors opened a new position in Third Harmonic Bio worth $43.3M.
- Bain Capital Life Sciences Investors's largest Q3 2022 buy was Third Harmonic Bio: 2,280,082 shares worth $43.3M.
- Bain Capital Life Sciences Investors added most to X4 Pharmaceuticals in Q3 2022, an estimated $3.88M increase.
- Bain Capital Life Sciences Investors's biggest Q3 2022 reduction was Dynavax Technologies, cutting an estimated $39.1M.
- Bain Capital Life Sciences Investors fully exited Research Alliance Corp. II Class A Common Stock in Q3 2022, selling an estimated $9.8M.
- Bain Capital Life Sciences Investors's ten largest holdings make up 68% of its $838M portfolio in Q3 2022.
- Bain Capital Life Sciences Investors opened 1 new position and closed 3 in Q3 2022.
- Bain Capital Life Sciences Investors's portfolio value fell 1.8% quarter-over-quarter to $838M.
Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2022, filed 14 Nov 2022.